Trials / Completed
CompletedNCT04635566
Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute
Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute. A Randomised Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Mansoura University · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this randomised trial, we hypothesised that mebeverine could enhance nocturnal continenece of Orthotopic Bladder Substitute (OBS) patients by decreasing the frequency and reduce maximum amplitude of uninhibited contractions of OBS ileum, and consequently it would increase the OBS capacity
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. | mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. |
| DRUG | Placebo | Placebo one time/day at the evening. |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2020-03-01
- Completion
- 2020-03-01
- First posted
- 2020-11-19
- Last updated
- 2020-11-19
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04635566. Inclusion in this directory is not an endorsement.